The (Re-)Discovery of 17{beta}-hydroxyestra-4,9,11-trien-3-one: Low Dose Trenbolone Safely Promotes Myotrophic Actions in Skeletal Muscle and Provides Partial Protection Against Bone Loss and Visceral Fat Accumulation
Sometimes it is interesting to see how agents that have been around all along reappear back on the medical scene, all of a sudden. A recent study conducted by a group of scientists from Florida ( Yarrow. 2011 ) that compared the effect of different doses of 17{beta}-hydroxyestra-4,9,11-trien-3-one aka Trenbolone on muscle hypertrophy and prostate health of testosterone seems to have the potential to trigger such a "revival": In both intact and orchiectomized animals, all TREN doses and supraphysiologic testosterone-enanthate augmented androgen-sensitive levator ani/bulbocavernosus muscle mass by 35-40% above Shams (p≤0.001), and produced a dose-dependent partial protection against orchiectomy-induced total and trabecular bone mineral density losses (<0.05) and visceral fat accumulation (<0.05). The lowest doses of TREN successfully maintained prostate mass and hemoglobin concent...